Mr. Steve Saviuk reports
VALEO PHARMA APPLIES FOR LISTING ON THE U.S. OTCQB MARKET
Valeo Pharma Inc. has completed and filed its application to list the company's Class A shares on the OTCQB market in the United States.
The listing of the company's shares on the OTCQB remains subject to the company fulfilling all of the listing requirements of the OTCQB and any other regulatory requirements. The company will continue to maintain the listing of its shares on the CSE under the symbol VPH.
"With growing U.S. investor interest in Valeo, we feel that the application to list our shares on the OTCQB at this time is a positive step forward towards providing both U.S. institutional and retail investors with a readily accessable trading platform for our securities," said Steve Saviuk, president and chief executive officer of Valeo Pharma.
Furthermore, the company granted 200,000 share options with an exercise price of $1.50 per share, expiring Oct. 31, 2020, as compensation to a non-related consultant providing media services.
About Valeo Pharma
Inc.
Valeo Pharma is a specialty pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on neurodegenerative diseases, oncology and hospital specialty products.
We seek Safe Harbor.
© 2024 Canjex Publishing Ltd. All rights reserved.